Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
Status:
Completed
Trial end date:
2019-07-08
Target enrollment:
Participant gender:
Summary
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to
evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis
(PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)